LGALS4, galectin 4, 3960

N. diseases: 73; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 Biomarker group BEFREE Detection of malignancy-associated phosphoproteome changes in human colorectal cancer induced by cell surface binding of growth-inhibitory galectin-4. 30550624 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 Biomarker group BEFREE Furthermore, galectin-4 engaged with C1GALT1-dependent O-glycans to promote castration resistance and metastasis by activating receptor tyrosine kinase signaling and cancer cell stemness properties mediated by SRY-box 9 (SOX9). 29906246 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 AlteredExpression group BEFREE The ectopic expression of gal-4 in cancer cell lines was used to address its biological function in UC in vitro. 28423602 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 AlteredExpression group BEFREE We show that abrogation of galectin-4 expression promotes cancer cell proliferation and, for the first time, provide evidence that down-regulation of galectin-4 elicits tumor promotion in vitro and in vivo through activation of IL-6/NF-κB/STAT3 signaling. 23378274 2013
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 AlteredExpression group BEFREE To ensure cancer-specific targeting, efficient delivery, and efficacy, we developed an ovarian cancer-specific construct (Survivin-VISA-hEndoyCD) composed of the cancer specific promoter survivin in a transgene amplification vector (VISA; VP16-GAL4-WPRE integrated systemic amplifier) to express a secreted human endostatin-yeast cytosine deaminase fusion protein (hEndoyCD) for advanced ovarian cancer treatment. hEndoyCD contains an endostatin domain that has tumor-targeting ability for anti-angiogenesis and a cytosine deaminase domain that converts the prodrug 5-fluorocytosine (5-FC) into the chemotherapeutic drug, 5-fluorouracil. 22562248 2013
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.060 AlteredExpression group BEFREE Galectin-4 in normal tissues and cancer. 15115909 2004